Michael Cherny
Stock Analyst at Leerink Partners
(4.21)
# 436
Out of 5,090 analysts
109
Total ratings
58.24%
Success rate
12.79%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $182.51 | +15.06% | 3 | Oct 21, 2025 | |
| MCK McKesson | Maintains: Outperform | $785 → $850 | $808.62 | +5.12% | 15 | Sep 24, 2025 | |
| CAH Cardinal Health | Maintains: Outperform | $188 → $186 | $198.83 | -6.45% | 13 | Aug 12, 2025 | |
| PGNY Progyny | Upgrades: Outperform | $28 | $24.02 | +16.57% | 11 | Jul 8, 2025 | |
| BOLD Boundless Bio | Downgrades: Market Perform | $15 → $3 | $1.14 | +163.16% | 2 | May 28, 2025 | |
| NVST Envista Holdings | Maintains: Buy | $26 → $23 | $20.23 | +13.69% | 11 | Apr 29, 2025 | |
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $548.12 | -39.79% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $39.20 | +2.04% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $75.63 | -0.83% | 11 | Feb 13, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $45.93 | +95.95% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $157.21 | +78.11% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $73.62 | +14.10% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $225.85 | +9.81% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $185.80 | +37.24% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.25 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $339.66 | -19.04% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $258.39 | +0.62% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.71 | +195.20% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $9.22 | +106.07% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $7.59 | +123.98% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $3.03 | +1,632.67% | 2 | Jan 5, 2022 |
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $182.51
Upside: +15.06%
McKesson
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $808.62
Upside: +5.12%
Cardinal Health
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $198.83
Upside: -6.45%
Progyny
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $24.02
Upside: +16.57%
Boundless Bio
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.14
Upside: +163.16%
Envista Holdings
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $20.23
Upside: +13.69%
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $548.12
Upside: -39.79%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $39.20
Upside: +2.04%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $75.63
Upside: -0.83%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $45.93
Upside: +95.95%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $157.21
Upside: +78.11%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $73.62
Upside: +14.10%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $225.85
Upside: +9.81%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $185.80
Upside: +37.24%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $11.25
Upside: -
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $339.66
Upside: -19.04%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $258.39
Upside: +0.62%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.71
Upside: +195.20%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $9.22
Upside: +106.07%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $7.59
Upside: +123.98%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $3.03
Upside: +1,632.67%